Journal:Laboratory testing methods for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

From LIMSWiki
Revision as of 19:19, 8 June 2020 by Shawndouglas (talk | contribs) (Saving and adding more.)
Jump to navigationJump to search
Full article title Laboratory testing methods for novel Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
Journal Frontiers in Cell and Developmental Biology
Author(s) D'Cruz, Roshan J.; Currier, Arthur W.; Sampson, Valerie B.
Author affiliation(s) Nemours/Alfred I. duPont Hospital for Children
Primary contact Email: valerie dot sampson at nemours dot org
Year published 2020
Volume and issue 8
Article # 468
DOI 10.3389/fcell.2020.00468
ISSN 2296-634X
Distribution license Creative Commons Attribution 4.0 International
Website https://www.frontiersin.org/articles/10.3389/fcell.2020.00468/full
Download https://www.frontiersin.org/articles/10.3389/fcell.2020.00468/pdf (PDF)
Emblem-important-yellow.svg This article should be considered a work in progress and incomplete. Consider this article incomplete until this notice is removed.

Abstract

Following the first reports of coronavirus disease 2019 (COVID-19) by China to the World Health Organization (WHO) on December 31, 2019, more than 4,302,774 cases of infection by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus have been reported by authorities in 212 countries and territories as of May 12, 2020. The outbreak and spread of COVID-19 worldwide highlights the critical need for developing rapid and accurate diagnostic testing methods for emerging human coronavirus (CoV) infections. Testing is crucial to tracking the spread of disease during a pandemic, and to swiftly permitting public health interventions, including isolation, quarantine, and appropriate clinical management of afflicted individuals. The key components of viral diagnostic tests are (1) collection of the appropriate sample (blood, nasal swab, and throat swab); (2) availability of the genetic and proteomic sequences of the novel virus for analysis; and (3) rapid and accurate laboratory testing methods. The current gold standard for the molecular diagnosis of SARS-CoV-2 infection is the real-time reverse transcription polymerase chain reaction (qRT-PCR) for the qualitative and quantitative detection of viral nucleic acids. Other relevant laboratory methods include enzyme-linked immunosorbent assays (ELISA) for viral antibody and antigen detection, and serum virus neutralization (SVN) assays for antibody neutralization determination. The challenges faced in developing a diagnostic test for a novel pathogen are the ability to measure low viral loads for early detection, to provide low or no cross-reactivity with other viral strains, and to deliver results rapidly. Several point-of-care molecular devices are currently being integrated for fast and accurate diagnosis of SARS-CoV-2 infections. This review discusses the current laboratory methods available to test for coronaviruses by focusing on the present COVID-19 outbreak.

Keywords: coronavirus, RT-PCR, ELISA, lateral flow diagnostics, convalescent plasma

Introduction

Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus (CoV) that was originally reported in Wuhan, Hubei province, China in December 2019.[1] The International Committee on Taxonomy of Viruses named the virus "severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infection by SARS-CoV-2 causes a respiratory illness that varies in severity from mild upper respiratory symptoms akin to the seasonal flu, to severe progressive respiratory failure that requires intensive care and can lead to death. Asymptomatic carriers of the virus have also been reported and pose a significant public health threat due to their ability to unknowingly spread the virus.[2] SARS-CoV-2 represents the third coronavirus in this millennium to cross species from animals to humans and cause a severe respiratory disease, after Middle-East respiratory syndrome coronavirus (MERS-CoV) in 2012[3] and severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003.[4][5] SARS-CoV-2 has now been identified as the seventh coronavirus that is transmissible between humans (a group which also includes HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1).[6] On January 30, 2020, the World Health Organization (WHO) declared the SARS-CoV-2 epidemic a public health emergency of international concern, and the public health emergency was upgraded to a pandemic on March 11. At least 4,302,774 confirmed cases and 289,561 deaths worldwide were reported as of May 12.<ref name="WorldCOVID">"COVID-19 Coronavirus Pandemic". Worldometer. https://www.worldometers.info/coronavirus/. Retrieved 12 May 2020.  >/ref> Diagnostic testing is critical during a pandemic as the ability to track the spread of SARS-CoV-2 is essential for effective disease management and control.


References

  1. ↑ World Health Organization (2020). "Naming the coronavirus disease (COVID-19) and the virus that causes it". World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Retrieved May 2020. 
  2. ↑ Chan, J.F.-W.; Yuan, S.; Kok, K.-H. et al. (2020). "A Familial Cluster of Pneumonia Associated With the 2019 Novel Coronavirus Indicating Person-To-Person Transmission: A Study of a Family Cluster". Lancet 395 (10223): 514–23. doi:10.1016/S0140-6736(20)30154-9. PMC PMC7159286. PMID 31986261. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159286. 
  3. ↑ Zaki, A.M.; van Boheemen, S.; Besterbroer, T.M. et al. (2012). "Isolation of a Novel Coronavirus From a Man With Pneumonia in Saudi Arabia". New England Journal of Medicine 367 (19): 1814–20. doi:10.1056/NEJMoa1211721. PMID 23075143. 
  4. ↑ Drosten, C.; Günther, S.; Preiser, W. et al. (2003). "Identification of a Novel Coronavirus in Patients With Severe Acute Respiratory Syndrome". New England Journal of Medicine 348 (20): 1967-76. doi:10.1056/NEJMoa030747. PMID 12690091. 
  5. ↑ Ksiazek, T.G.; Erdman, D.; Goldsmith, C.S. et al. (2003). "A Novel Coronavirus Associated With Severe Acute Respiratory Syndrome". New England Journal of Medicine 348 (20): 1953–66. doi:10.1056/NEJMoa030781. PMID 12690092. 
  6. ↑ Salata, c.; Calistri, A.; Parolin, C. et al. (2019). "Coronaviruses: A Paradigm of New Emerging Zoonotic Diseases". Pathogens and Disease 77 (9): ftaa006. doi:10.1093/femspd/ftaa006. PMC PMC7108526. PMID 32065221. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108526. 

Notes

This presentation is faithful to the original, with only a few minor changes to presentation. In some cases important information was missing from the references, and that information was added. References in this version are listed in order of appearance—by design—rather than alphabetical order as the original was.

Retrieved from "https://www.limswiki.org/index.php?title=Journal:Laboratory_testing_methods_for_novel_severe_acute_respiratory_syndrome_coronavirus_2_(SARS-CoV-2)&oldid=39603"